Tim Peterson
9.6K posts

Tim Peterson
@timrpeterson
Programming, molecular biology @bioio_tech timrpeterson.eth @vita_dao



Over 50,000 people in the U.S. die from pancreatic cancer every year. After this drug is approved and widely used, that number will remain essentially the same. In absolute terms, they are reporting a median survival shift of around six months. Yet we know resistance inevitably develops, as it does in all cancers subjected to drugs targeting mutations in the RAS/MAPK/PI3K pathway. If the goal is to meaningfully reduce cancer mortality, this does not move the needle. This is where decades of focus and billions in NIH/NCI funding have concentrated. National Cancer Institute is funded at roughly $9 billion per year, and a substantial portion of that budget is devoted to oncogenes and what is marketed as targeted therapies. This is then layered on top of a drug development and healthcare model where drugs like this can cost over $100,000 per patient. These are incremental gains at the late metastatic stage, where the biology is already stacked against you. Meanwhile, the two areas that actually determine population-level outcomes—early detection and prevention—remain neglected. If we are serious about reducing the number of people who die from pancreatic cancer, the priority cannot be continuing to optimize late-stage interventions that predictably yield temporary gains. The goal should be zero deaths. Right now, we are not on a path that gets us there. It is not surprising that this view is being met with backlash. Much of the criticism is coming from people whose incentives—academic , financial, or institutional—are tied to maintaining the current system in biomedical research and the biotech and pharma sectors that profit from it.











Prediction markets for clinical trials sound like forecasting. But they’re really betting on patient lives. This introduces financial incentives that can distort science, undermine clinical equipoise, and erode trust. Medicine should not be a casino. youtu.be/MfuyQaJli88




Something huge just landed at @ResearchHub. Introducing: Endowments. Starting today, everyone holding ResearchCoin (RSC) in their ResearchHub account will automatically earn high-yield Funding Credits, distributed daily. Funding Credits must be used to support projects on ResearchHub, turning your one-time investment into a continuous source of research funding.

Someone created an interesting LLM pipeline to map drugs to genetic evidence from public resource, inspired by my Works In Progress article on human genetics and drug discovery. I am yet to try this one myself, but the fact that someone outside the field got interested in genetics and went on to create this resource is the highest impact I can hope for my writing!


Alzheimer’s is one of the most devastating diseases, killing ~2 million people globally each year and costing over $1 trillion annually. It also remains one of the hardest unsolved problems in medicine. We believe advanced AI can help change that: openaifoundation.org/news/ai-for-al…








